Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.80% | 12.06% | 27.96% | -11.63% | -1.76% |
| Total Depreciation and Amortization | 8.53% | 0.87% | 596.97% | -85.80% | 4.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -75.38% | 45.41% | -38.98% | 31.86% | 97.34% |
| Change in Net Operating Assets | 552.76% | 108.13% | -686.27% | -130.95% | 1,748.00% |
| Cash from Operations | -1.40% | 82.83% | -13.07% | -33.30% | 28.94% |
| Capital Expenditure | -6.95% | -30.31% | 54.48% | -73.83% | -23.46% |
| Sale of Property, Plant, and Equipment | 0.00% | -90.00% | -78.72% | 4,600.00% | -97.30% |
| Cash Acquisitions | 100.06% | -- | -- | -634.48% | 98.24% |
| Divestitures | -481.82% | -175.00% | -102.44% | 2,242.86% | 126.92% |
| Other Investing Activities | -86.55% | -141.18% | 125.58% | -75,233.33% | -100.90% |
| Cash from Investing | 61.66% | -779.70% | 110.88% | -710.96% | 88.34% |
| Total Debt Issued | -84.12% | 52.88% | 2,416.67% | -100.65% | 20.64% |
| Total Debt Repaid | 3.44% | 38.00% | -1,215.85% | 92.93% | 47.49% |
| Issuance of Common Stock | -90.00% | 1,900.00% | -- | -100.00% | -80.00% |
| Repurchase of Common Stock | 15.18% | 0.07% | 1.67% | 3.22% | -76.61% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 53.40% | -- | -- | -- |
| Other Financing Activities | 110.23% | -1,034.78% | 117.97% | -197.67% | -72.00% |
| Cash from Financing | 46.50% | 39.01% | -185.31% | -684.29% | 88.06% |
| Foreign Exchange rate Adjustments | -105.76% | 112.22% | 157.32% | -278.41% | 617.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 807.32% | 90.67% | -104.33% | -137.68% | 464.37% |